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Abstract
Variability in response to drug use is common and heritable, suggesting that genome-wide 
pharmacogenomics studies may help explain the “missing heritability” of complex traits. Here, we 
describe four independent analyses in 33,781 participants of European ancestry from ten cohorts 
that were designed to identify genetic variants modifying the effects of drugs on QT interval 
duration (QT). Each analysis cross-sectionally examined four therapeutic classes: thiazide 
diuretics (prevalence of use=13.0%), tri/tetracyclic antidepressants (2.6%), sulfonylurea 
hypoglycemic agents (2.9%), and QT prolonging drugs as classified by the University of Arizona 
Center for Education and Research on Therapeutics (4.4%). Drug-gene interactions were 
estimated using covariable adjusted linear regression and results were combined with fixed-effects 
meta-analysis. Although drug-SNP interactions were biologically plausible and variables were 
well-measured, findings from the four cross-sectional meta-analyses were null 
(Pinteraction>5.0×10−8). Simulations suggested that additional efforts, including longitudinal 
modeling to increase statistical power, are likely needed to identify potentially important 
pharmacogenomic effects.
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INTRODUCTION
The role of inheritance in response to drug exposure has long been appreciated, dating to as 
early as 1932 when the inability to taste phenylthiocarbamide was demonstrated to follow an 
autosomal recessive inheritance pattern.1 Today, the promise of pharmacogenomics lies in 
its potential to tailor drug prescription and dosing to individual patients,2–4 a practice 
exemplified by the use of a patient’s genotype to inform warfarin dosing,5, 6 to avoid anemia 
during hepatitis C treatment,7 or to predict benefit from and therefore guide chemotherapy in 
breast cancer.8 Documented heterogeneity of drug response has also prompted the 
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suggestion that examining drug-gene interactions may help explain a notable proportion of 
the heritability for complex traits that remains unexplained by genome wide association 
(GWA) studies.9, 10 Yet to date, large scale pharmacogenomics studies are few in number.11
The duration of the QT interval (QT), a non-invasive measure of the ventricular action 
potential estimated from the resting, standard twelve-lead electrocardiogram (ECG), offers a 
good model for examining the value of pharmacogenomics. In addition to being well-
measured,12 heritable,13, 14 and heterogeneous among those exposed to what are now called 
“QT-prolonging drugs”,15 QT prolongation is the most common cause of withdrawal or 
restricted marketing of pharmaceuticals16 largely because of its established association with 
ventricular tachyarrhythmia,17 sudden cardiac death, and all-cause mortality.18, 19, 20 
However, prospectively identifying subpopulations at risk for drug-induced QT prolongation 
and its sequelae remains a challenge.16
Although heritability estimates suggest a substantial genetic component underlying QT, 
genetic variation at the 26 single nucleotide polymorphisms (SNPs) identified to date by 
GWA studies together explain approximately 5–8% of the variance in QT.21–27 Popular 
explanations for this missing heritability include rare variants that are poorly represented on 
commercial genotyping arrays as well as gene-gene and gene-environment interactions.10 In 
search of this missing heritability, we assessed pharmacogenomic influences on QT by 
conducting four cross-sectional GWA analyses in ten populations of European ancestry. The 
goal of the studies was to identify genetic variants modifying the association between drugs 
in four therapeutic classes previously associated with QT prolongation or sudden death28–32 
and the duration of QT.
METHODS
Study populations
A meta-analysis of ten cohorts with GWA data that included 33,781 participants of 
European descent was performed to investigate cross-sectional drug-SNP interactions in QT. 
Five cohorts were from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium:33 the Age, Gene/Environment Susceptibility – 
Reykjavik Study (AGES), the Atherosclerosis Risk in Communities study (ARIC), the 
Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), and the Rotterdam 
Study (RS). Since the inception of CHARGE, five additional cohorts have joined the effort: 
the Erasmus Rucphen Family study (ERF), Health 2000, the Health Aging, Body and 
Composition (Health ABC) study, the Multi-Ethnic Study of Atherosclerosis (MESA), and 
the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). At baseline for all 
cohorts, drug exposure was queried and participants underwent standardized ECGs, which 
were read for QT duration. Each cohort followed a pre-specified analysis protocol and 
findings from the within-cohort analyses were then combined by meta-analysis. All studies 
were approved by local ethics committees and all participants provided written informed 
consent. Additional information on the participating studies is provided in the 
Supplementary Material.
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Study design; inclusion and exclusion criteria
Within each cohort, we performed four separate cross-sectional analyses using drug, 
covariate, and ECG data collected at the baseline examination. Participants with the 
following characteristics were excluded from the analysis: poor quality ECG, extreme QRS 
duration prolongation including that due to bundle branch block (QRS > 120 ms), atrial 
fibrillation/flutter on ECG, paced rhythm, or second or third degree atrioventricular block. 
Heart failure at study baseline was an additional exclusion for the thiazide diuretic, 
sulfonylurea hypoglycemic agent, and tri/tetracyclic antidepressant analyses. Users of loop 
diuretics, regardless of thiazide use, also were excluded from analyses examining thiazide 
diuretics.
Definition of drug exposure
Drug use was assessed by method of medication inventory or pharmacy database 
(Supplemental Table 1). Six of the nine cohorts using the medication inventory method 
captured medications used within one to two weeks preceding ECG assessment. The 
remaining three cohorts currently using medication inventory methods assessed medications 
used on the day of ECG recording. The Rotterdam Study was the only cohort that assessed 
drug exposure via pharmacy databases; investigators classified a participant as exposed if 
he/she filled a prescription for a drug class of interest within 30 days preceding the ECG 
recording.
Four classes of therapeutic drugs previously associated with QT prolongation were 
examined: thiazide diuretics,30, 32 tri/tetracyclic antidepressants,31 sulfonylurea 
hypoglycemic agents,29 and University of Arizona Center for Education and Research on 
Therapeutics (UAZ CERT)-classified QT prolonging drugs.28 Participants were classified: 
as thiazide users if they took a thiazide or thiazide-like diuretic in a single or combination 
preparation, with or without potassium sparing diuretic or potassium supplements; as 
sulfonylurea users if they took a first or second generation sulfonylurea anti-diabetic; and as 
tri/tetracyclic users if they took a tricyclic or tetracyclic antidepressant, ignoring 
concomitant use of other therapeutic drug classes.
The UAZ CERT classification was used to group medications into four classes based on the 
likelihood of QT-prolongation: definite, possible, conditional, or no/unknown. Participants 
using two or more drugs classified as conditional were reclassified as possible. When 
participants took drugs from more than one UAZ CERT class, the highest class was 
assigned. For the UAZ CERT analyses, participants classified as users of definite or possible 
QT prolonging drugs were classified as exposed; participants classified as no/unknown were 
classified as unexposed; and those reporting use of one conditional QT prolonging agent 
were excluded.
QT measurement
For each study, technicians digitally recorded resting, supine (or semi-recumbent), standard 
twelve-lead ECGs for each participant (Supplementary Table 2) on the same day drug 
exposure was recorded. Studies used comparable procedures for preparing participants, 
placing electrodes, recording, transmitting, processing and controlling quality of the ECGs, 
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although QT in the various studies was measured by different automated systems and 
therefore will be subject to a small variation equivalent to inter observer error. The ECG 
from the baseline visit was selected when multiple ECGs were available.
Genotype arrays and imputation
Genome-wide SNP genotyping was performed within each cohort using either the 
Affymetrix or Illumina genotyping arrays (Supplemental Table 3). Gender mismatches and 
duplicate samples were excluded. First-degree relatives were excluded in all cohorts except 
the family-based FHS and ERF, which accounted for relatedness in the association analysis. 
DNA samples with genotyping success rates between <95% and <99%, depending on the 
cohort, were excluded. SNPs also were excluded when genotyping call rate thresholds were 
between 95% and 99%, and minor allele frequencies (MAF) ≤ 1%, the determination of 
which was cohort-specific.
To increase coverage and facilitate evaluation of the same SNPs across cohorts, genotypes 
were imputed using BIMBAM,34 MACH35 or BEAGLE,36 which applied algorithms that 
inferred unobserved genotypes in a probabilistic manner. Imputation was performed for ~2.5 
million autosomal SNPs based on the HapMap Phase 2 (build 36) CEU reference population 
(Supplemental Table 3).
Statistical analysis
Each cohort performed four GWA analyses of QT across approximately 2.5 million SNPs 
comparing drug users to non-users. Study designs that restricted to those on treatment were 
not chosen because of the large potential for type I error due to the inseparability of the SNP 
main effect and interaction effect estimates.37 Each drug-genotype interaction was estimated 
using linear regression, under an additive genetic model, and using robust standard errors 
except in the family-based FHS and ERF cohorts, which used linear mixed-effects models as 
implemented in the GWAF package for R (FHS)38 and GenABEL/ProbABEL (ERF).39, 40 
All regressions adjusted for the following covariates: age (year), sex, RR interval (ms), 
recruitment site when appropriate, and principal components summarizing participants’ 
global genetic ancestry to account for confounding by race/ethnicity. Additionally, the four-
category UAZ CERT drug categorization was included as a nominal covariate in the 
thiazides, sulfonylureas, and tri/tetracyclic analyses.
For some SNPs, the numbers of genetic variants among participants on drug therapy were 
too small to permit use of standard asymptotic results. Therefore, cohort-specific inference 
used a (Student’s) t as the reference distribution. The degrees of freedom for the t reference 
distribution were calculated as the cohort- and SNP-specific product of: the number of drug-
exposed participants, the SNP imputation quality (range: 0, 1), and the MAF (range: 0, 
0.50). For each SNP, cohort-specific P-values were calculated by comparing β/standard 
error estimates to this reference, with the resulting P-values then meta-analyzed using the 
standard weighted Z-statistic method,41 with weights based on the number exposed to the 
drug multiplied by the SNP imputation quality.
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Cohort-specific results were corrected by their respective genomic inflation factors (λs).42 
The genome-wide threshold for significant drug-SNP interaction was P < 5.0 × 10−8. The 
software packages R, ProbABEL, GenABEL, PLINK, and GRIMP were used to estimate 
cohort-specific results (Supplemental Table 3) and METAL41 was used to generate 
summary meta-analytic estimates of the drug-SNP interaction parameters. Quantile-quantile 
(Q-Q) plots were used to identify systematic miscalibration of the test statistic for the drug-
genotype interactions.
Statistical power simulations
Power to detect drug-SNP interactions using cross-sectional and longitudinal modeling 
approaches was estimated via simulation studies. Assumptions, which were informed by 
study data, included: (1) 20,000–30,000 participants, (2) a two-sided, per-SNP α = 5.0 × 
10−8, (3) a mean heart-rate corrected QT (standard deviation) = 426 (20) ms, (4) a 
prevalence of drug exposure = 0.10 for the longitudinal simulations and 0.03 – 0.14 for the 
cross-sectional simulations, (5) a mean drug effect for those with zero copies of the minor 
allele = 1 ms, (6) a mean SNP effect for those not exposed to drug = 1, (7) a MAF = 0.20 for 
the longitudinal simulations and MAF 0.05–0.30 for the cross-sectional simulations, and (8) 
an additive model of inheritance. The drug-SNP interaction effect was varied in size. To 
evaluate the power that could be gained by incorporating repeated measures over time, the 
simulation incorporated up to 2–6 measurements of QT duration and drug exposure for each 
participant, and the within-person correlation in QT was set at 0.5 based on unpublished 
observations. Drug use was either temporally constant or variable. When variable, drug 
exposure was assumed to be completely random at each time. An attrition rate of 5% per 
visit, plus random missingness of 5% of remaining measurements, was assumed. Linear 
models with robust standard errors were used for cross-sectional analyses, and generalized 
estimating equations (GEE) with exchangeable working correlation were used for 
longitudinal analyses.
RESULTS
GWA analyses were performed to examine whether common genetic variants modified the 
effects of exposure to drugs in four therapeutic classes on QT. The ten participating cohorts 
of European descent varied in size (range: 1,435 – 8,132, Table 1). On average, participants 
were predominantly female (percent female range: 49.4%–62.5%) and middle-aged to 
elderly (mean age range = 40–75 years). The estimated prevalence of drug exposure at study 
baseline was highest for thiazides (13.6%), lowest for the tri/tetracyclics (2.6%), and 
intermediate for the sulfonylurea hypoglycemic agents (2.9%) and UAZ CERT-classified 
QT-prolonging drugs (4.4%). After applying genotyping and imputation quality control 
measures, a total of approximately 2.5 million autosomal SNPs were available for analysis.
Quantile-quantile plots based on meta-analyses of the cohort-specific, drug-SNP interaction 
test statistics revealed moderately conservative distributions, as demonstrated by λ < 1.0 
(range: 0.89–0.99) and slightly earlier departure of P-values in the direction of conservatism, 
compared to what would have been expected by chance alone (Figure 1). In line with 
statistical theory, overstated significance due to miscalibration, which was common using 
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standard asymptotic methods, was not observed using the t-reference approach. These 
patterns did not differ by the prevalence of medication use at study baseline.
No genome-wide significant cross-sectional interactions (P < 5.0 × 10−8) were detected for 
any of the four drug classes (Figure 2). The top five loci (Supplemental Table 4) also were 
inconsistent across drug classes. Cross-sectional meta-analyses restricted to the 26 SNPs 
reported by previously published GWA studies of QT main effects were similarly null 
(interaction P ≥ 0.01, Table 2), as were results for SNPs reported by recent 
pharmacogenomic studies of QT and drug-induced QT prolongation (Supplemental Table 
5).43–47
Statistical power
Given the robustly null results and because four cohorts (52.2% of total sample size) had 
repeated ECG recordings and drug exposure assessments (range: 2, 10; Supplemental Table 
2), we examined statistical power for the cross-sectional analysis and the degree to which 
analyses incorporating repeated measures would increase statistical power. Simulations 
demonstrated that all cross-sectional analyses were underpowered, especially for drug 
categories with 3% prevalence (Supplemental Figure 1). However, when the prevalence of 
drug use increased to 14% (e.g. thiazides) and the SNP was common, we achieved 80% 
power to detect an effect of 3.25 ms. Incorporating repeat ECG measures with constant drug 
exposure yielded a moderate increase in statistical power, although the greatest increase was 
associated with a time-varying drug exposure, i.e. observed QT measurement on and off 
drug within an individual (Figure 3). For example, we had > 80% power to detect interactive 
drug-SNP effects less than 2 ms when a time-varying drug exposure was examined at least 
four different times.
DISCUSSION
In this study composed of approximately 35,000 participants of European descent from ten 
cohorts, we examined cross-sectional evidence for drug-SNP interactions influencing QT. 
We did not identify any variants that significantly modified the association between QT and 
drugs in four therapeutic classes previously associated with QT prolongation. An analysis 
limited to SNPs with previously identified genome-wide significant main effects yielded 
similarly null results, as did one restricted to recent pharmacogenomic studies of QT and 
drug-induced QT prolongation.43–47
It remains unclear how much “missing heritability” future gene-environment interaction 
studies will explain, as GWA studies of interaction effects are only beginning to emerge. 
Drug exposure likely represents a good candidate for gene-environment interrogation, as 
medication use is highly prevalent48, 49 and pharmacogenomics is one of the few fields in 
which gene-environment interactions have been consistently replicated across studies.50–54 
It is also biologically plausible that the human genome contains variants that modify the 
association between drug exposure and phenotype, as such common variant alleles would 
have emerged long before the appearance of modern pharmacotherapies.55
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We chose a well-measured phenotype12 with biologically plausible pharmacogenomic 
effects15 and our drug assessment methods were sensitive and reliable,56, 57 yet were unable 
to detect any genome-wide significant interactions. One possible explanation is statistical 
power. Using stringent genome-wide significance thresholds, we remained underpowered to 
detect cross-sectional interactions below six ms for low prevalence drugs (e.g. the 
sulfonylurea hypoglycemic agents, UAZ CERT, and tri/tetracyclic antidepressants analyses). 
Although 80% power is achieved when a more common drug exposure is examined (e.g. 
thiazides), three ms is outside the range of typical genetic effects observed for QT.
Statistical power remains a challenge in gene-environment interaction studies, although the 
potential utility of longitudinal models to increase power has been shown here and described 
previously.58 Increases in power from longitudinal models are due in part to increased 
precision in outcome measurement; but when exposure varies over time, power increases are 
also due to within-person comparisons of the outcome under each drug status. Therefore, 
longitudinal analyses increase power more than expanding sample sizes when there is 
variability in exposure over time and minimal concern about time-dependent confounding 
that would complicate the interpretation of longitudinal estimates. Analyses of drug-gene 
interaction effects on QT satisfy both conditions. However, longitudinal models remain rare 
in GWA studies examining both main and interactive effects and likely reflect the 
considerable computational complexities associated with implementing a longitudinal model 
that accommodates the scale of a typical GWA study. We are currently developing methods 
to implement longitudinal analyses on a genome-wide scale and future work will include re-
evaluation of gene-drug interactions on QT interval using available longitudinal data.
In addition to performing a GWA study of QT-prolonging drug use and QT, as a sensitivity 
analysis we separately evaluated 26 SNPs previously associated with QT main effects. 
Restricting interaction analyses to SNPs with replicated main effects is not uncommon in 
GWA interaction studies,59 and likely reflects statistical power concerns given the stringent 
GWA study significance thresholds. Here, we demonstrated that none of the previously 
identified QT SNPs modified the association between QT prolonging drug use and QT. This 
is not surprising, as SNPs selected on the basis of an extreme P-value for a single main 
effect may be less likely to harbor heterogeneity across population subgroups.
Several limitations of the present study warrant consideration to inform future efforts 
examining pharmacogenomic influences on QT. First, we did not address the potential for 
bias related to duration of use. It is difficult to gauge the overall influence of duration of use 
effects, in which participants taking the drugs for years or decades are those least likely to 
have experienced side effects, as they likely differ by drug class. For example, intraclass 
correlation coefficients (ICC) estimated in the ARIC study suggest intermittent patterns of 
use for the UAZ CERT class (ICC =0.39), but long-term usage patterns for thiazide diuretics 
(ICC = 0.69). Although we can suppose that drugs with intermittent patterns of use are less 
influenced by selection bias related to duration of use than those characterized by long-term 
usage patterns, further studies examining the robustness of pharmacogenomic findings to 
such biases are clearly warranted. Second, confounding by contraindication also could result 
from the comorbidities that influence drug use and QT. However, previous simulations 
indicated that confounding by contraindication has very modest effects on estimates of 
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interaction in pharmacogenomic studies.37 Third, our results are statistically conservative, 
given the evidence of under-statement of significance for the drug-SNP interaction estimates 
suggested by QQ plots. However, it is unlikely that the bias would be so large as to cause 
truly genome-significant loci to be reclassified as non-significant. Fourth, we relied on 
medication inventory and pharmacy data to ascertain medication usage. Although neither 
source of information guarantees exposure, validation studies suggest good agreement 
between serum drug concentrations and several (e.g. thiazide diuretic) exposures ascertained 
by medication inventory.56 Pharmacy data appear to be even more accurate in this regard.60
Finally, the drug classes considered herein, particularly the UAZ CERT class, combine QT-
prolonging drugs that may have heterogeneous mechanisms of action, thereby reducing the 
sensitivity for detecting SNPs possessing important, population-level interactive effects. 
However, disagreement among classifications is much lower in the highest ventricular 
arrhythmia risk category16 and for older drugs, including the majority of those taken by 
participants at the time of their past examinations. Relatively systematic attempts to 
exhaustively identify, classify, and update current lists of QT-prolonging medications in 
pharmacologically more meaningful ways are also unavailable. Moreover, nearly all drugs 
that prolong QT and cause ventricular arrhythmias inhibit the rapidly activating delayed 
rectifier potassium current.16, 61
In conclusion, our findings suggest that additional efforts are required to realize the potential 
of pharmacogenomics. In addition to careful selection of the phenotype of interest, 
researchers interested in pharmacogenomics should increase the number of measures per 
participant and invest in longitudinal modeling infrastructure scalable to GWA studies to 
help increase statistical power. Although these cross-sectional analyses do not support 
strong drug-gene interactions for QT, future efforts incorporating longitudinal modeling are 
needed to determine whether the reported associations are underpowered or genuinely null.
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FIGURE 1. 
Quantile-quantile (Q-Q) plots of drug-SNP interaction estimates after meta-analysis of 
summary results from ten cohorts of European descent. Drug classes are as follows: panel A, 
thiazide diuretics; panel B, sulfonylurea hypoglycemic agents; panel C, University of 
Arizona Center for Education and Research on Therapeutics (UAZ CERT)-classified QT 
prolonging drugs; panel D, tri/tetracyclic antidepressants.
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FIGURE 2. 
Manhattan plots of drug-SNP interaction estimates after meta-analysis of summary results 
from ten cohorts of European descent. Drug classes are as follows: panel A, thiazide 
diuretics; panel B, sulfonylurea hypoglycemic agents; panel C, University of Arizona Center 
for Education and Research on Therapeutics (UAZ CERT)-classified QT prolonging drugs; 
panel D, tri/tetracyclic antidepressants.
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FIGURE 3. 
Statistical power of a simulated pharmacogenomics study of QT. The following assumptions 
were used for the calculations; 2–6 serial visits measuring ECGs and drug exposure, 
n=20,000–30,000 participants, a SNP minor allele frequency of 0.20, and the prevalence of 
drug exposure at any one visit of 10%. The solid black lines represent a cross-sectional 
analysis, the red lines a longitudinal model evaluating drug exposure measured at baseline 
and repeated ECG measures, and the blue lines a longitudinal model with drug exposure and 
ECG assessed at all visits. Figure 3A assumes 20,000 participants, with variable number of 
visits. Figure 3B assumes four visits, with a variable number of participants.
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